Skip to main content
. 2011 Jan 25;19(4):650–657. doi: 10.1038/mt.2010.312

Figure 2.

Figure 2

In vivo analyses of vvCCL5 in tumor-bearing mice. (a) CCL5 levels in tumor samples from MC38 tumor-bearing C57/BL6 mice, treated with intraperitoneal injections of vvCCL5, phosphate buffered saline (PBS) or vvDD (P < 0.02). (b) Antitumor effects of vvCCL5. vvCCL5, vvDD, and PBS delivered via intraperitoneal injection into MC38 tumor-bearing C57/BL6 mice. vvCCL5 showed significant tumor suppression and significantly enhanced survival than vvDD-treated mice (P < 0.03 for vvCCL5 relative to vvDD at all time points after 18 days) (n = 10/group). (c) Biodistribution of vvCCL5 or vvDD after intraperitoneal injections into MC38 tumor-bearing C57/BL6 mice. Mice killed at indicated time points and organs recovered, ground to release viral virions, and titered by plaque assay (n = 3). PFU, plaque forming unit; MFI.